Remise de seringues et de traitements à la méthadone pour les personnes toxicomanes : enquête nationale pharmacies 2005 et monitoring des autres sources d'approvisionnement en matériel d'injection

ans le cadre du mandat de l'Office fédéral de la santé publique (OFSP) concernant le système de suivi de la stratégie de lutte contre le VIH/Sida en Suisse, 2004-2008, l'Institut universitaire de médecine sociale et préventive (IUMSP) de Lausanne a fait une estimation de l'évolution du nombre total de seringues stériles utilisées en Suisse à des fins d'injection de substances psychotropes, que ces injections soient contrôlées ou non. Les sources utilisées sont : le monitoring national de la distribution de seringues dans les structures à bas seuil (SBS), l'enquête nationale auprès des pharmacies, l'estimation du nombre de seringues utilisées par les participants du programme de thérapie (Programme de prescription médicale d'héroïne - PROVE, puis Traitement avec prescription d'héroïne - HeGeBe)

Toxicomanie dans le canton de Vaud : cinquième période d'évaluation 2004-2006. Cahier 1

Les objectifs de l'évaluation pour la période 2004-2006 étaient les suivants : suivre l'évolution de la situation épidémiologique de la toxicomanie dans le canton de Vaud en s'appuyant sur les données existantes. - Répéter l'enquête sur les comportements des consommateurs de drogue dans les structures à bas seuil effectuée régulièrement dans le cadre d'une enquête nationale. - Evaluer l'émergence de nouvelles demandes de prise en charge et de nouveaux modes de consommation problématique sans héroïne. - Suivre l'évolution des structures de traitement et d'accueil à bas seuil. - Analyser la prise en charge par les médecins praticiens. - Contribuer à la réflexion sur l'apport de mesures de réduction des risques et de traitement en complément au dispositif actuel (locaux d'injection et prescription d'héroïne sous contrôle médical). [Extrait Introduction p. 5]]]> Substance-Related Disorders ; Substance Abuse Treatment Centers ; Prisons ; Syringes ; Evaluation Studies ; Switzerland ; Vaud fre https://serval.unil.ch/resource/serval:BIB_33A1F8396319.P001/REF.pdf http://nbn-resolving.org/urn/resolver.pl?urn=urn:nbn:ch:serval-BIB_33A1F83963193 info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_33A1F83963193 info:eu-repo/semantics/submittedVersion info:eu-repo/semantics/openAccess Copying allowed only for non-profit organizations https://serval.unil.ch/disclaimer application/pdf oai:serval.unil.ch:BIB_33A255F82CDD 2022-05-07T01:14:47Z <oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"> https://serval.unil.ch/notice/serval:BIB_33A255F82CDD Caspase-induced inactivation of the anti-apoptotic TRAF1 during Fas ligand-mediated apoptosis. info:doi:10.1016/S0014-5793(00)01206-0 info:eu-repo/semantics/altIdentifier/doi/10.1016/S0014-5793(00)01206-0 info:eu-repo/semantics/altIdentifier/pmid/10692572 Irmler, M. Steiner, V. Ruegg, C. Wajant, H. Tschopp, J. info:eu-repo/semantics/article article 2000 FEBS Letters, vol. 468, no. 2-3, pp. 129-133 info:eu-repo/semantics/altIdentifier/pissn/0014-5793 urn:issn:0014-5793 <![CDATA[The activation of the transcription factor NF-kappaB often results in protection against apoptosis. In particular, pro-apoptotic tumor necrosis factor (TNF) signals are blocked by proteins that are induced by NF-kappaB such as TNFR-associated factor 1 (TRAF1). Here we show that TRAF1 is cleaved after Asp-163 when cells are induced to undergo apoptosis by Fas ligand (FasL). The C-terminal cleavage product blocks the induction of NF-kappaB by TNF and therefore functions as a dominant negative (DN) form of TRAF1. Our results suggest that the generation of DN-TRAF1 is part of a pro-apoptotic amplification system to assure rapid cell death

Report on the first round of the Mock LISA Data Challenges

The Mock LISA Data Challenges (MLDCs) have the dual purpose of fostering the development of LISA data analysis tools and capabilities, and demonstrating the technical readiness already achieved by the gravitational-wave community in distilling a rich science payoff from the LISA data output. The first round of MLDCs has just been completed: nine data sets containing simulated gravitational wave signals produced either by galactic binaries or massive black hole binaries embedded in simulated LISA instrumental noise were released in June 2006 with deadline for submission of results at the beginning of December 2006. Ten groups have participated in this first round of challenges. Here we describe the challenges, summarise the results, and provide a first critical assessment of the entries.Comment: Proceedings report from GWDAW 11. Added author, added reference, clarified some text, removed typos. Results unchanged; Removed author, minor edits, reflects submitted versio

Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment.

BACKGROUND: The recording of outcomes from large-scale, simplified HAART (highly active antiretroviral therapy) programmes in sub-Saharan Africa is critical. We aimed to assess the effectiveness of such a programme held by Médecins Sans Frontières (MSF) in the Chiradzulu district, Malawi. METHODS: We scaled up and simplified HAART in this programme since August, 2002. We analysed survival indicators, CD4 count evolution, virological response, and adherence to treatment. We included adults who all started HAART 6 months or more before the analysis. HIV-1 RNA plasma viral load and self-reported adherence were assessed on a subsample of patients, and antiretroviral resistance mutations were analysed in plasma with viral loads greater than 1000 copies per mL. Analysis was by intention to treat. FINDINGS: Of the 1308 patients who were eligible, 827 (64%) were female, the median age was 34.9 years (IQR 29.9-41.0), and 1023 (78%) received d4T/3TC/NVP (stavudine, lamivudine, and nevirapine) as a fixed-dose combination. At baseline, 1266 individuals (97%) were HAART-naive, 357 (27%) were at WHO stage IV, 311 (33%) had a body-mass index of less than 18.5 kg/m2, and 208 (21%) had a CD4 count lower than 50 cells per muL. At follow-up (median 8.3 months, IQR 5.5-13.1), 967 (74%) were still on HAART, 243 (19%) had died, 91 (7%) were lost to follow-up, and seven (0.5%) discontinued treatment. Low body-mass index, WHO stage IV, male sex, and baseline CD4 count lower than 50 cells per muL were independent determinants of death in the first 6 months. At 12 months, the probability of individuals still in care was 0.76 (95% CI 0.73-0.78) and the median CD4 gain was 165 (IQR 67-259) cells per muL. In the cross-sectional survey (n=398), 334 (84%) had a viral load of less than 400 copies per mL. Of several indicators measuring adherence, self-reported poor adherence (<80%) in the past 4 days was the best predictor of detectable viral load (odds ratio 5.4, 95% CI 1.9-15.6). INTERPRETATION: These data show that large numbers of people can rapidly benefit from antiretroviral therapy in rural resource-poor settings and strongly supports the implementation of such large-scale simplified programmes in Africa

HIBISCUS: Hydroxychloroquine for the secondary prevention of thrombotic and obstetrical events in primary antiphospholipid syndrome

The relapse rate in antiphospholipid syndrome (APS) remains high, i.e. around 20%-21% at 5 years in thrombotic APS and 20-28% in obstetrical APS [2, 3]. Hydroxychloroquine (HCQ) appears as an additional therapy, as it possesses immunomodulatory and anti-thrombotic various effects [4-16]. Our group recently obtained the orphan designation of HCQ in antiphospholipid syndrome by the European Medicine Agency. Furthermore, the leaders of the project made the proposal of an international project, HIBISCUS, about the use of Hydroxychloroquine in secondary prevention of obstetrical and thrombotic events in primary APS. This study has been launched in several countries and at now, 53 centers from 16 countries participate to this international trial. This trial consists in two parts: a retrospective and a prospective study. The French part of the trial in thrombosis has been granted by the French Minister of Health in December 2015 (the academic trial independent of the pharmaceutical industry PHRC N PAPIRUS) and is coordinated by one of the members of the leading consortium of HIBISCUS

Activités de Médecins sans Frontières à Homa Bay (soins apportés aux personnes séropositives pour le VIH)

BORDEAUX2-BU Santé (330632101) / SudocPARIS-BIUM (751062103) / SudocSudocFranceF

Système de suivi de la stratégie de lutte contre le VIH/sida en Suisse : rapport de synthèse 2004-2008

[Table des matières] 1. Résumé des principaux résultats. 2. Introduction. 3. Epidémiologie du VIH/sida. 4. Hommes ayant des relations sexuelles avec des hommes (HSH). 5. Usagers de drogue par voie intraveineuse (UDI). 6. Migrants. 7. Prostitution. 8. Personnes vivant avec le VIH/sida (PVA). 9. Population générale. 10. Jeunes de 17 à 20 ans. 11. Comportements sexuels dans le contexte du VIH/sida : évolution avec l'âge. 12. Conclusions et recommandations. 13. Bibliographie. 14. Annexes

Estimating national-level syringe availability to injecting drug users and injection coverage: Switzerland, 1996-2006.

BACKGROUND: Measuring syringe availability and coverage is essential in the assessment of HIV/AIDS risk reduction policies. Estimates of syringe availability and coverage were produced for the years 1996 and 2006, based on all relevant available national-level aggregated data from published sources. METHODS: We defined availability as the total monthly number of syringes provided by harm reduction system divided by the estimated number of injecting drug users (IDU), and defined coverage as the proportion of injections performed with a new syringe, at national level (total supply over total demand). Estimates of supply of syringes were derived from the national monitoring system, including needle and syringe programmes (NSP), pharmacies, and medically prescribed heroin programmes. Estimates of syringe demand were based on the number of injections performed by IDU derived from surveys of low threshold facilities for drug users (LTF) with NSP combined with the number of IDU. This number was estimated by two methods combining estimates of heroin users (multiple estimation method) and (a) the number of IDU in methadone treatment (MT) (non-injectors) or (b) the proportion of injectors amongst LTF attendees. Central estimates and ranges were obtained for availability and coverage. RESULTS: The estimated number of IDU decreased markedly according to both methods. The MT-based method (from 14,818 to 4809) showed a much greater decrease and smaller size of the IDU population compared to the LTF-based method (from 24,510 to 12,320). Availability and coverage estimates are higher with the MT-based method. For 1996, central estimates of syringe availability were 30.5 and 18.4 per IDU per month; for 2006, they were 76.5 and 29.9. There were 4 central estimates of coverage. For 1996 they ranged from 24.3% to 43.3%, and for 2006, from 50.5% to 134.3%. CONCLUSION: Although 2006 estimates overlap 1996 estimates, the results suggest a shift to improved syringe availability and coverage over time